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SATU  PERBANDINGAN RAWATAN FARMAKOLOGI, PENGETAHUAN DAN 
GAYA HIDUP DALAM KALANGAN PESAKIT-PESAKIT DIABETIK DENGAN 
MIKROALBUMINURIA DI EMPAT HOSPITAL DI INDIA DAN MALAYSIA 
 
 
ABSTRAK 
 
Nefropati diabetik adalah salah satu komplikasi mikrovaskular yang utama dalam 
kalangan pesakit diabetik. Ahli epidemiologi meramalkan bahawa individu yang 
mengalami diabetes dalam populasi dunia akan mencecah 300 juta menjelang tahun 2025 
dan hampir separuh daripadanya adalah dari benua Asia. Malaysia dan India terletak di 
tangga teratas dalam senarai penularan diabetik dengan India digelar ‘Ibu kota diabetik 
sedunia’. Pelbagai cara telah dikaji dalam pelbagai bidang yang berkaitan komplikasi 
diabetik namun keputusannya masih kurang jelas. Oleh yang demikian, suatu kajian 
terkumpul dan perbandingan telah direka untuk merumus rawatan farmakologi, 
pengetahuan dan gaya hidup pesakit diabetik dengan mikroalbuminuria dengan kaedah 
pengesanan awal status komplikasi bagi mengelak atau memperlahankan perkembangan 
nefropati diabetic. 
 
Kajian prospektif diskriptif garis lintang dan kajian cohort telah dijalankan dengan 
menggunakan teknik persampelan mudah di empat buah hospital di India dan Malaysia. 
Bagi mengumpul maklumat, satu borang pengumpul data yang standard telah direka dan 
dibahagikan kepada dua bahagian. Bahagian pertama mengumpul informasi tentang 
modul sosio-demografik dan modul rawatan serta diagnosis daripada rekod-rekod 
perubatan pesakit. Bahagian kedua melibatkan soal selidik yang mengumpul maklumat 
tentang ilmu pesakit dan modifikasi gaya hidup dengan cara menemuramah para pesakit. 
 xxiii 
Hasil keputusan dianalisis secara statistik dengan menggunakan perisian Statistical 
Package for the Social Sciences (SPSS), versi 15. 
Sejumlah 3358, pesakit diabetik telah dihampiri untuk kajian ini yang mana 1025 pesakit 
telah didiagnos dengan mikroalbuminuria. Oleh yang demikian mereka telah 
dipertimbangkan untuk kajian penuh di India dan Malaysia. Min umur pesakit diabetik 
dengan nefropati di hospital kerajaan dan swasta di India dan Malaysia adalah 46.32±9.36 
tahun, 44.34±8.01 tahun and 57.26±11.38 tahun, 55.45±10.31 tahun masing-masing. 
Penularan nefropati dalam kalangan pesakit di India didapati bermula pada umur yang 
lebih muda jika dibandingkan pesakit di Malaysia. Faktor-faktor risiko pesakit nefropati 
diabetik di keempat-empat hospital adalah umur, jantina, bangsa (p<0.05), sejarah 
keluarga, kemiskinan, diet, indeks massa tubuh (BMI), merokok, pengambilan alkohol, 
senaman, pematuhan terhadap pengambilan ubatan. Kesan faktor bangsa yang diperolehi 
dalam kajian pesakit Malaysia menunjukkan bahawa dalam ketiga-tiga bangsa (Melayu, 
Cina dan India), orang Melayu lebih cenderung mendapat masalah mikrovaskular diikuti 
dengan orang Cina dan sangat rendah dalam kalangan orang India (p=0.048). 
Sulphonylureas and perencat ACE masing-masing digunakan secara meluas untuk 
rawatan nefropati diabetik di kedua-dua negara. Analisis mendedahkan bahawa pesakit 
dengan perencat ACE yang menerima sulphonylurea (p<0.001), pioglitazone (p<0.05), 
dan insulin (p<0.05) menunjukkan keputusan yang lebih baik dalam kesemua tiga 
parameter (glukos darah, tekanan darah dan mikroalbumin) apabila dibandingkan dengan 
ubat-ubat kelas lain. Kajian yang dibuat terhadap pengetahuan dan gaya hidup dalam 
populasi multietnik Malaysia yang berkongsi konteks sosio-budaya yang sama mendapati 
bahawa latar belakang etnik mempengaruhi kualiti gaya hidup secara signifikan. Daripada 
keempat-empat hospital, pesakit-pesakit dari hospital kerajaan India mendapat skor 
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terendah dalam pengetahuan dan modifikasi gaya hidup (p<0.001). Kemiskinan adalah 
faktor utama yang memberi kesan terhadap gaya hidup mereka. 
 
Akhir sekali, kesimpulannya adalah, pesakit-pesakit diabetik di kedua-dua negara 
menerima jenis rawatan yang sama dan mempunyai pengetahuan yang secukupnya 
tentang penyakit tersebut tetapi tidak mempraktikkannya dalam kehidupan seharian 
mereka untuk meneruskan gaya hidup yang baik dan sihat. 
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A COMPARISON OF PHARMACOLOGICAL TREATMENT, KNOWLEDGE 
AND LIFE STYLE MODIFICATION AMONG DIABETIC PATIENTS WITH 
MICROALBUMINURIA IN FOUR HOSPITALS IN INDIA AND MALAYSIA 
 
 
ABSTRACT 
 
Diabetic nephropathy is one of the major microvascular complications in diabetic patients. 
Epidemiologist predicts that the world population of diabetic individuals will swell up to 
an astounding 300 million by the year 2025 and almost half of that will be in the Asian 
region alone. Malaysia and India are ranked top in the list for the high prevalence of 
diabetes with India being termed as the “diabetes capital of the world”. Interventions have 
been extensively studied in different areas of diabetic complications, but still results 
remained unclear. Therefore a collective and comparative study is designed to resolute the 
pharmacological treatment, knowledge and life style among diabetic patients with 
microalbuminuria by early detection of the complication status to prevent or delay the 
progression of diabetic nephropathy. 
 
A prospective, cross sectional descriptive and a cohort study was conducted by using 
convenience sampling technique in four hospitals in India and Malaysia. To collect the 
information, a standard data collection form was developed and was divided into two 
parts. The first part was to gather information on socio-demographic as well as treatment 
module and diagnosis from the patient medical records. The second part involved 
questionnaires which collected the information about the patient knowledge and life style 
modification by interviewing the patients. Results were analyzed statistically using 
Statistical Package for the Social Sciences (SPSS) software version 15. 
A total of 3358 diabetic patients were approached for the study out of which 1025 patients 
were diagnosed with microalbuminuria, therefore were taken into consideration for the 
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complete study in India and Malaysia. The mean age of the diabetic patients with 
nephropathy in government, private hospital in India and Malaysia, was found to be 
46.32±9.36 years, 44.34±8.01 years and 57.26±11.38 years, 55.45±10.31 years 
respectively. The progression of nephropathy in Indian patients was found to be in early 
ages compared to Malaysian patients. The risk factors of diabetic neprhopathy patients 
found in all the four hospitals were age, gender, family history, poverty, diet, BMI, 
smoking, alcohol intake, exercise, medicine compliance, and race (p<0.05). The effect of 
race was found in the Malaysian study, which shows that within the three different races 
(Malay, Chinese, and Indian) Malays are more prone to microvascular complications 
followed by Chinese and least found to be in Indians (p=0.048). Sulphonylureas and ACE 
inhibitors were used most widely for the treatment of diabetes and nephropathy 
respectively in both the countries. The analysis revealed that the patients with ACE 
inhibitors receiving sulphonylurea (p<0.001), pioglitazone (p<0.05), and insulin (p<0.05) 
showed better results on all three parameters (blood glucose, blood pressure and 
microalbuminuria) when compared to other class of drugs. The survey conducted on 
knowledge and life style in multiethnic Malaysian population sharing the same socio-
cultural context, found that ethnicity significantly influenced quality of lifestyle. Among 
the four hospitals, the patients from government hospital in India had lowest scores in 
knowledge and life style modification (p<0.001). Poverty was the main impact which 
affected their life style. 
Finally, it is concluded that the diabetic patients in both the countries received a similar 
kind of treatment and have sufficient knowledge on the disease but are not implementing 
it in their daily life to maintain a good and healthy life style.  
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Chapter-1: INTRODUCTION 
 
1.1   An Overview on Renal Disease 
Nephropathy is a medical term used to refer to disease or damage in the kidneys. The 
kidneys act as one of the filtration systems in the body, expressing undesirable substances 
and retaining useful ones in addition to maintaining normal blood pressure levels. They 
also produce urine, a fluid which is used to express substances which are not needed by 
the body. When the kidneys are damaged, the lack of filtration resulting from it can make 
people extremely sick. People may develop nephritis, an inflammation of the kidneys, and 
this can progress to a full-blown nephropathy (Goodman et al., 2004). 
In some cases, nephropathy is congenital, caused by a genetic problem which interferes 
with kidney function. Many congenital forms of nephropathy involve enzyme deficiencies 
which make it difficult for the body to process certain compounds. People can also 
acquire disease or damage through the use of certain drugs or lead exposure (Stephanie S 
Taber & Deborah A Pasko, 2008). Nephropathy is a very common complication of 
diabetes, resulting from damage to the kidneys caused by high blood sugar, and people 
with high blood pressure can also develop nephropathy. 
One common form of nephropathy is Berger's disease, also known as IgA nephropathy, 
(Melk A, 2003) in which an antibody known as IgA builds up in the kidneys, impairing 
kidney function and causing an inflammation of some of the structures inside the kidneys. 
These Conditions can be diagnosed through samples of blood and urine, along with 
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biopsies, ultrasounds, and other studies which are designed to determine the functions of 
the body (Lamb et al., 2003). 
Treatments are usually focused on determining the cause of the nephropathy and treating 
it. If the kidneys are overloaded with something the body cannot process, some of the 
kidneys fuction could partly be performed by dialysis. In extreme cases, kidney transplant 
is a treatment option for people with damaged kidneys that independent recovery is 
unlikely.  
Because of the crucial role of the kidney in filtering blood, a wide range of systemic 
diseases and disease of other organ systems may be manifested most prominently in the 
kidney. Thus, renal disease is a prominent presentation of long-standing diabetes mellitus, 
hypertension, and autoimmune disorders such as systemic lupus erythematosus (Julio 
Avila, et al., 2008). 
Without treatment, renal disease may result in sufficient loss of kidney functions. 
However, not all renal disease has an inexorable downhill course and dismal outcome. 
The consequences of renal disease depend on the extent and nature of the injury and its 
natural history and time course. Some forms of renal disease are transient. Even when 
severe, they may be self-limited and reversible and, if managed properly, may have no 
permanent bad consequences (Lai et al., 2005). Other forms progress eventually to renal 
failure, either rapidly or slowly, with a host of metabolic and hemodynamic consequences 
along the way. When renal disease progresses, there can be loss of aspects of renal 
filtration capacity (eg, disordered regulation of body electrolyte and volume status) as 
well as loss of nonexcretory renal functions such as the production of erythropoietin 
(resulting in anemia). The anatomic unit of kidney function is the nephron, a structure 
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consisting of a tuft of capillaries termed the glomerulus, the site at which blood is filtered, 
and a renal tubule from which water and salts in the filtrate are reclaimed. Each human 
kidney has approximately 1 million nephrons. 
A glomerulus consists of an afferent and an efferent arteriole and an intervening tuft of 
capillaries lined by endothelial cells and covered by epithelial cells that form a continuous 
layer with those of Bowman's capsule and the renal tubule. The space between capillaries 
in the glomerulus is called the mesangium. Material comprising a basement membrane is 
located between the capillary and the epithelial cells. (Klahr S, 2002). Closer examination 
of glomerular histology and cell biology reveals features not found in most peripheral 
capillaries. First, the glomerular capillary endothelium is fenestrated. However, because 
the endothelial cells have a coat of negatively charged glycoproteins and 
glycosaminoglycans, they normally exclude plasma proteins such as albumin. On the 
other side of the glomerular basement membrane are the epithelial cells. (Christensen CK 
& Mogensen CE, 1985; Tremblay R, 2004). The mesangium is an extension of the 
glomerular basement membrane but is less dense and contains two distinct cell types: 
intrinsic glomerular cells and tissue macrophages. Both cell types contribute to the 
development of immune-mediated glomerular disease by their production of, and 
response to, cytokines such as transforming growth factor-  (Melk A, 2003). 
The complex organization of the glomerulus is crucial not only for renal function but also 
for explaining the differences observed in glomerular disease. Thus, in some conditions 
immune complexes may accumulate under the epithelial cells, whereas in others they 
accumulate under the endothelial cells. Likewise, because immune cells are not able to 
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cross the glomerular basement membrane, immune complex deposition under the 
epithelial cells is generally not accompanied by a cellular inflammatory reaction. 
The renal tubule itself has a number of different structural regions: the proximal 
convoluted tubule, from which approximately 80% of the electrolytes and water are 
reclaimed; the loop of Henle; and a distal convoluted tubule and collecting duct, where 
the urine is concentrated and additional electrolyte and water changes are made in 
response to hormonal control (Lewis EJ et al., 1993). 
1.1.1   Renal Regulation of Blood Pressure 
The kidney plays an important role in blood pressure regulation by virtue of its effect on 
sodium ion (Na+) balance, a major determinant of blood pressure. First, the Na+ 
concentration in the proximal tubular fluid is sensed at the macula densa, part of the 
juxtaglomerular apparatus. The juxtaglomerular apparatus also assesses the perfusion 
pressure of the blood, an important indicator of intravascular volume status under normal 
circumstances. Through the action of these two sensors, either low Na+ or low perfusion 
pressure acts as a stimulus to renin release. Renin, a protease made in the juxtaglomerular 
cells, cleaves angiotensinogen in the blood to generate angiotensin I, which is then 
cleaved to angiotensin II by angiotensin-converting enzyme (ACE). Angiotensin II raises 
blood pressure by triggering vasoconstriction directly and by stimulating aldosterone 
secretion, resulting in Na+ and water retention by the collecting duct. All of these effects 
expand the extracellular fluid (ECF) and hence renal perfusion pressure, completing a 
homeostatic negative feedback loop that alleviates the initial stimulus for renin release 
(Lai et al., 2005). 
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Intravascular volume depletion also triggers vasopressin release. Receptors in the carotid 
body and elsewhere sense a fall in blood pressure and activate autonomic neural 
pathways, including fibers that go to the hypothalamus, where vasopressin release is 
controlled. Vasopressin is released and travels via the bloodstream throughout the body. 
At the collecting duct renal tubular apical plasma membrane, vasopressin facilitates 
insertion of water channels, thereby increasing the number of water channels. This results 
in reabsorption of free water (Lewis EJ et al., 1993). 
1.1.2   Regulation of Renal Function 
There are a variety of physical, hormonal, and neural mechanisms by which the functions 
of the kidney are controlled. Vasopressin, together with the physics of the countercurrent 
multiplier in the loop of Henle and the hypertonic medullary interstitium, makes it 
possible to concentrate the urine under normal circumstances. This confers on the normal 
kidney the ability to maintain fluid homeostasis under widely diverse conditions by 
generating either concentrated or dilute urine, depending on whether the body needs to 
conserve or excrete salt and water (Ljungman et al., 1980). 
Tubuloglomerular feedback refers to the ability of the kidney to regulate the glomerular 
filtration rate (GFR) in response to the solute concentration in the distal renal tubule. 
When an excessive concentration of Na+ in the tubular fluid is sensed by the macula 
densa, afferent arteriolar vasoconstriction is triggered. This diminishes the GFR so that 
the renal tubule has a smaller solute load per unit time, allowing Na+ to be more 
efficiently reclaimed from tubular fluid. A variety of vasoactive substances, including 
prostaglandins, nitric oxide, and peptides such as endothelin and bradykinin, contribute to 
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the humoral control of tubuloglomerular feedback (Pedersen EB and Mogensen 
CE.,1976). 
Another important challenge for the kidney is regulation of renal cortical versus 
medullary blood flow. Renal cortical blood flow needs to be sufficient to maintain a GFR 
high enough to clear renally excreted wastes efficiently without exceeding the capacity of 
the renal tubules for solute reabsorption. Likewise, medullary blood flow must be closely 
regulated. Excessive medullary blood flow can disrupt the osmolar gradient achieved by 
the countercurrent exchange mechanism. Insufficient medullary blood flow can result in 
anoxic injury to the renal tubule. From the perspective of individual nephrons, 
redistribution of blood flow from cortex to medulla involves preferentially supplying 
blood (and, therefore, oxygen) to those nephrons with long Loops of Henle that dip down 
into the inner medulla. (Prakash J. et al., 2006) 
Most medullary oxygen consumption goes to generate the adenosine triphosphate (ATP) 
that fuels the array of active transporters involved in reabsorption of solute in the loop of 
Henle. Thus, when oxygen demand exceeds available supply, regulatory mechanisms tend 
to limit the workload of the ATP-consuming transporters. These regulatory mechanisms 
diminish the solute delivered to the loop of Henle (ie, by decreasing GFR). Renal blood 
flow is also preferentially shunted to medullary nephrons. In times of excessive oxygen 
demand, mediators are released, resulting in vasoconstriction of some vascular beds and 
vasodilation of others. This serves to both decrease GFR and, at the same time, 
redistribute blood flow from cortex to medulla (Pedersen EB and Mogensen CE.,1976). 
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1.1.3 Mechanisms underlying the decline in kidney function 
There is no clear-cut consensus about what mechanisms may underlie the structural and 
functional changes occurring in the kidney in the older population. It is fairly clear 
however that there are both predisposing genetic and environmental factors that play a 
role (Levey AS et al., 2005). 
1.1.3 (a) Predisposing Factors 
It has been well known for many years that several diseases predispose to kidney failure 
and will accelerate the progress of age-related glomerulosclerosis. By far the most 
frequent of these are hypertension and diabetes, both common disorders in the older 
population. There are however several other mechanisms that have been postulated to 
underlie the aging changes in the kidney (U.S. Department of Health and Human 
Services, 2000). 
1.1.3 (b) Free radicals and lipid peroxides 
One possible explanation for the profound effects of calorie restriction is a reduction in 
the generation of free radicals and lipid peroxides. There is a wide body of literature 
discussing the damaging effects of free radicals on cellular systems and the role that this 
plays in aging. The main consequence of free radical production is lipid peroxidation, 
which results in damage to cellular proteins, lipids, and nucleic acids. Increased calorie 
intake is believed to fuel increased free radical production with accelerated aging damage. 
This hypothesis has generated interest in the role of antioxidants in slowing the aging 
process (Perneger et al., 1995). 
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1.1.3 (c) Protein restriction 
The benefits of calorie restriction have been attributed to concomitant reductions in 
dietary protein. Clearly, protein restriction does have some benefit in the prevention of 
age-related nephropathy, but that advantage is small compared to those achieved with 
caloric restriction. (Perneger et al., 1995) 
1.1.3 (d) Lipids 
There is a well-established link between lipids and cardiovascular disease, and restriction 
of fat intake accompanied by treatment of hyperlipidemia has been shown to be 
efficacious in preventing or slowing the progress of cardiovascular disease. Certainly 
protecting the integrity and function of the vascular supply to the kidney is important to 
maintaining normal function. Patients with established renal disease with or without 
diabetes have more rapid deterioration of kidney function in the presence of 
hyperlipidemia. The relevance of lipids to the age-related decline in kidney function 
remains to be established, but it would certainly be reasonable to recommend low-fat diet 
and lipid management in patients with declining renal function (Perneger et al., 1995). 
 
 
 
 
 
 
 9 
1.2   Pharmacoepidemiology 
1.2.1  Definition 
Pharmacoepidemiology is the study of the use of and the effects of drugs in large number 
of people. The term pharmacoepidemiology obviously contains two components: 
“pharmaco” and “epidemiology”. Thus pharmacoepidemiology is a relatively new applied 
field, bridging between clinical pharmacology and epidemiology. From clinical 
pharmacology, pharmacoepidemiology borrows its focus of inquiry. From epidemiology, 
pharmacoepidemiology borrows its methods of inquiry. The field of 
pharmacoepidemiology uses the techniques of chronic disease epidemiology to study the 
use of and the effects of drugs.  Pharmacoepidemiology has primarily been in context of 
post marketing drug surveillance (Brain L.Strom, 2005). 
1.2.2   Contributions of Pharmacoepidemiology 
The potential contributions of pharmacoepidemiology are only beginning to be realized, 
as the field is new. Premarketing studies of drug effects are necessarily limited in size. 
After marketing, non-experimental epidemiologic studies can be performed, evaluating 
the effects of drugs administered as part of ongoing medical care. As an academic or a 
clinician, one is most interested in the new information about drug effects and drug costs 
that can be gained from pharmacoepidemiology. In an era of product liability litigation, 
this is an important assurance for looking any undiscovered problems which may be there. 
Pharmacoepidemiology study designs the investigator does not control the therapy, but 
simply observes and evaluates the results of ongoing medical care. Certainly, these are the 
findings that receive the greatest public and political attention. Moreover the field is 
expanding its focus to include many issues other than adverse reactions (Fletcher et al., 
1996). 
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1.2.3   Study designs 
Epidemiological studies can be divided into two main types:  
1. Descriptive epidemiology describes disease and/or exposure and may consist of 
calculating rates, e.g., incidence and prevalence. Such descriptive studies do not use 
control groups and can only generate hypotheses, not test them. Studies of drug utilization 
would generally fall under descriptive studies (Brain L.Strom, 2005;  Collett JP & Boissel 
JP, 1991). 
 
2. Analytic epidemiology includes two types of studies: observational studies, such as 
case-control and cohort studies, and experimental studies which would include clinical 
trials such as randomized clinical trials. The analytic studies compare an exposed group 
with a control group and are usually designed as hypothesis testing studies (Brain 
L.Strom, 2005;  Collett JP & Boissel JP, 1991). 
 
Pharmacoepidemiology benefits from the methodology developed in general 
epidemiology and may further develop them for applications of such methodology unique 
to pharmacoepidemiology. There are also some areas that are altogether unique to 
pharmacoepidemiology, e.g., pharmacovigilance. Pharmacovigilance is a type of 
continual monitoring for unwanted effects and other safety-related aspects of drugs that 
are already on the market. In practice, pharmacovigilance refers almost exclusively to the 
spontaneous reporting systems which allow health care professionals and others to report 
adverse drug reactions to a central agency (Fletcher et al., 1996). 
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1.2.4   Perspectives on Pharmacoepidemiology 
As the programs of pharmacoepidemiology study are expanded and developed, it is 
important that their effects are rigorously evaluated. There are several obvious roles of 
pharmacoepidemiologists in this process. These include drug utilization studies as part of 
a program to improve the quality of use of medicines, designing interventions to improve 
prescribing, the conduct and evaluation of pharmacoeconomic studies, and identifying and 
quantifying adverse drug reactions. In developing countries, there is still a need for 
adverse reaction reporting as part of the process to identify failure in the quality of 
producing sound data. 
The future of pharmacoepidemiology seems apparent in many ways, judging from the past 
trends and recent events. Interest in the field by the pharmaceutical industry, government 
agencies, new trainees, and the public is truly exploding, as is realization of what 
pharmacoepidemiology can contribute. Thus from the perspective of academia, the 
pharmaceutical industry, regulatory agencies, and then the law in the field, the future of 
pharmacoepidemiology looks remarkably bright, although many important challenges 
remain (Brain L.Strom, 2005). 
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1.3   Diabetes Mellitus 
1.3.1   Definition 
Diabetes Mellitus is a syndrome which is caused by relative absence or lack of insulin. 
Clinically it is defined as a group of metabolic diseases characterized by high blood sugar 
(glucose) levels, which result from defects in insulin secretion, or action, or both. Diabetes 
mellitus, commonly referred to as diabetes, was first identified as a disease associated 
with “sweet urine," and excessive muscle loss in the ancient world. Elevated levels of 
blood glucose (hyperglycemia) lead to spillage of glucose into the urine, hence the term 
sweet urine. Normally, blood glucose levels are tightly controlled by insulin, a hormone 
produced by the pancreas. Insulin lowers the blood glucose level. When the blood glucose 
elevates (for example, after eating food), insulin is released from the pancreas to 
normalize the glucose level. In patients with diabetes, the absence or insufficient 
production of insulin causes hyperglycemia. Diabetes is a chronic medical condition, 
meaning that although it can be controlled, it lasts a lifetime (International Diabetes 
Federation, 1999; American Diabetes Association, 2007). 
1.3.2   Types of Diabetes 
Generally there are two major types of diabetes, called type 1 and type 2 diabetes. Type 1 
diabetes (previously known as insulin-dependent or childhood-onset diabetes) is 
characterized by a lack of insulin production. Type 2 diabetes (formerly called non-
insulin-dependent or adult-onset diabetes) is caused by the body’s ineffective use of 
insulin. It often results from excess body weight and physical inactivity (American 
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Diabetes Association, 2007, Diagnosis and classification of diabetes mellitus). Gestational 
diabetes is hyperglycemia that is first recognized during pregnancy.   
Type 1 diabetes was also called insulin dependent diabetes mellitus (IDDM), or juvenile 
onset diabetes mellitus. In type 1 diabetes, the pancreas undergoes an autoimmune attack 
by the body itself, and is rendered incapable of making insulin. Abnormal antibodies have 
been found in the majority of patients with type 1 diabetes. Antibodies are proteins in the 
blood that are part of the body's immune system. The patient with type 1 diabetes must 
rely on insulin medication for survival.  
Type 2 diabetes was also referred to as non-insulin dependent diabetes mellitus (NIDDM), 
or adult onset diabetes mellitus (AODM). In type 2 diabetes, patients can still produce 
insulin, but do so relatively inadequately for their body's needs. In many cases this 
actually means the pancreas produces larger than normal quantities of insulin. A major 
feature of type 2 diabetes is a lack of sensitivity to insulin by the cells of the body 
(particularly fat and muscle cells). In addition to the problems with an increase in insulin 
resistance, the release of insulin by the pancreas may also be defective and suboptimal. In 
fact, there is a known steady decline in beta cell production of insulin in type 2 diabetes 
that contributes to worsening glucose control. This is a major factor for many patients 
with type 2 diabetes who ultimately require insulin therapy. Finally, the liver in these 
patients continues to produce glucose through a process called gluconeogenesis despite 
elevated glucose levels. The control of gluconeogenesis becomes compromised.  
While that type 2 diabetes occurs mostly in individuals over 30 years old and the 
incidence increases with age, we are seeing an alarming number patients with type 2 
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diabetes who are barely in their teen years. In fact, for the first time in the history of 
humans, type 2 diabetes is now more common than type 1 diabetes in childhood. Most of 
these cases are a direct result of poor eating habits, higher body weight, and lack of 
exercise.  
While there is a strong genetic component to developing this form of diabetes, there are 
other risk factors - the most significant of which is obesity. There is a direct relationship 
between the degree of obesity and the risk of developing type 2 diabetes, and this holds 
true in children as well as adults. It is estimated that the chance to develop diabetes 
doubles for every 20% increase over desirable body weight (Evans et al., 2000) 
Regarding age, data shows that for each decade after 40 years of age regardless of weight 
there is an increase in incidence of diabetes. The prevalence of diabetes in persons 65 to 
74 years of age is nearly 20%. Type 2 diabetes is also more common in certain ethnic 
groups. Finally, diabetes occurs much more frequently in women with a prior history of 
diabetes that develops during pregnancy. 
Diabetes can occur temporarily during pregnancy. Significant hormonal changes during 
pregnancy can lead to blood sugar elevation in genetically predisposed individuals. Blood 
sugar elevation during pregnancy is called gestational diabetes. Gestational diabetes 
usually resolves once the baby is born. However, 25-50% of women with gestational 
diabetes will eventually develop Type 2 diabetes later in life, especially in those who 
require insulin during pregnancy and those who remain overweight after their delivery. 
Patients with gestational diabetes are usually asked to undergo an oral glucose tolerance 
test about 6 weeks after giving birth to determine if their diabetes has persisted beyond the 
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pregnancy, or if any evidence (such as impaired glucose tolerance) is present that may be 
a clue to the patient's future risk for developing diabetes (American Diabetes Association. 
Preconception care of women with diabetes, 2004). 
"Secondary" diabetes refers to elevated blood sugar levels from another medical 
condition. Secondary diabetes may develop when the pancreatic tissue responsible for the 
production of insulin is destroyed by disease, such as chronic pancreatitis (inflammation 
of the pancreas by toxins like excessive alcohol), trauma, or surgical removal of the 
pancreas. Diabetes can also result from other hormonal disturbances, such as excessive 
growth hormone production (acromegaly) and Cushing's syndrome. In acromegaly, a 
pituitary gland tumor at the base of the brain causes excessive production of growth 
hormone, leading to hyperglycemia. In Cushing's syndrome, the adrenal glands produce 
an excess of cortisol, which promotes blood sugar elevation (AACE, 2007)  
1.3.3   Symptoms of diabetes 
The early symptoms of untreated diabetes are related to elevated blood sugar levels, and 
loss of glucose in the urine. High amounts of glucose in the urine can cause increased 
urine output and lead to dehydration. Dehydration causes increased thirst and water 
consumption. The inability of insulin to perform normally has effects on protein, fat and 
carbohydrate metabolism. Insulin is an anabolic hormone, that is, one that encourages 
storage of fat and protein. A relative or absolute insulin deficiency eventually leads to 
weight loss despite an increase in appetite. Some untreated diabetes patients also complain 
of fatigue, nausea and vomiting. Patients with diabetes are prone to developing infections 
of the bladder, skin, and vaginal areas. Fluctuations in blood glucose levels can lead to 
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blurred vision. Extremely elevated glucose levels can lead to lethargy and coma. 
(American Diabetes Association., Standards for medical care in diabetes, 2007) 
1.3.4   Screening and diagnosis 
Any person found to have symptoms of diabetes mellitus (tiredness, lethargy, polyuria, 
polydipsia, polyphagia, weight loss, pruritus vulvae, balanitis) must be screened 
(American Diabetes Association, ADA 2004). 
 
Any person who presents to a primary care facility for any reason, without symptoms 
of diabetes, but has any ONE of the following risk factors should be screened: 
• Age 35 years or older 
• Pre-obese, BMI > 23 kg/m2 
• History of Gestational Diabetes Mellitus 
• History of big baby (birth weight ≥ 4.0kg) 
• History of diabetes mellitus in first degree relatives (parents, siblings) 
• Hypertension (140/90 mmHg) 
• Hyperlipidaemia 
• Dyslipidaemia either HDL-cholesterol < 0.9 or Triglyceride > 1.7 mmol/L 
 
Pregnant women should be screened at least once at > 24 weeks of gestation. 
Screening at an earlier stage of gestation depends on degree of suspicion and at the 
physician’s / obstetrician’s request (American Diabetes Association 2007, Diagnosis and 
classification of diabetes mellitus). 
 17 
The fasting blood glucose (sugar) test is the preferred way to diagnose diabetes. It is easy 
to perform and convenient. After the person has fasted overnight (at least 8 hours), a 
single sample of blood is drawn and sent to the laboratory for analysis. This can also be 
done accurately in a doctor's office using a glucose meter. 
Normal fasting plasma glucose levels are less than 100 milligrams per deciliter (mg/dl). 
Fasting plasma glucose levels of more than 126 mg/dl on two or more tests on different 
days indicate diabetes. A random blood glucose test can also be used to diagnose diabetes. 
A blood glucose level of 200 mg/dl or higher indicates diabetes.  
When fasting blood glucose stays above 100mg/dl, but in the range of 100-126mg/dl, this 
is known as impaired fasting glucose (IFG). While patients with IFG do not have the 
diagnosis of diabetes, this condition carries with it its own risks and concerns, and is 
addressed elsewhere.  
Though not routinely used anymore, the oral glucose tolerance test (OGTT) is a gold 
standard for making the diagnosis of type 2 diabetes. It is still commonly used for 
diagnosing gestational diabetes. With an oral glucose tolerance test, the person fasts 
overnight (at least eight but not more than 16 hours). Then first, the fasting plasma 
glucose is tested. After this test, the person receives 75 grams of glucose (100 grams for 
pregnant women). There are several methods employed by obstetricians to do this test, but 
the one described here is standard. Usually, the glucose is in a sweet-tasting liquid that the 
person drinks. Blood samples are taken at specific intervals to measure the blood glucose 
(AACE medical guidelines, 2007). 
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Glucose tolerance tests may lead to one of the following diagnoses:  
A person is said to have a normal response when the 2-hour glucose level is less than 140 
mg/dl or 7.7 mmol/L, and all values between 0 and 2 hours are less than 200 mg/dl or 11 
mmol/L (Malaysian Clinical Practice Guidelines: Management of Diabetic Nephropathy, 
2004). 
A person is said to have impaired glucose tolerance when the fasting plasma glucose is 
less than 126 mg/dl or 6.9 mmol/L and the 2-hour glucose level is between 140 and 199 
mg/dl or 7.7 and 11 mmol/L. 
A person has diabetes when two diagnostic tests done on different days show that the 
blood glucose level is high. ( ie when 2- hr glucose level is more than 140mg/dl or 7.7 
mmol/L) 
A woman has gestational diabetes when she has any two of the following: 100g OGTT, 
fasting plasma glucose of more than 95 mg/dl or 5.2 mmol/L, 1-hour glucose level of 
more than 180 mg/dl or 10 mmol/L, a 2-hour glucose level of more than 155 mg/dl or 8.6 
mmol/L, or a 3-hour glucose level of more than 140 mg/dl or 7.7 mmol/L (American 
Diabetes Association 2007, Diagnosis and classification of diabetes mellitus). 
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Figure 1.1: Screening for type 2 Diabetes Mellitus at Primary Care Level – with 
symptoms 
     With Symptoms 
   Capillary Plasma Glucose 
          Random            Fasting 
          Venous Plasma Glucose 
         Fasting           Random 
<5.6 mmol/L 
≥11.1 mmol/L 
 
<11.1 mmol/L 
 
<11.1 mmol/L 
 
≥11.1 mmol/L 
 
≥5.6 mmol/L 
<11.1 mmol/L 
 
≥11.1 mmol/L 
 
< 7.0 mmol/L 
 
≥ 7.0 mmol/L 
 
        Diabetes Mellitus 
                                                    Oral Glucose Tolerance Test 
2- hour Post Plasma Glucose 
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(Source: Adapted from Appendix 1a, Clinical practice guidelines, Malaysia 2004) 
 
 
Figure 1.2: Screening for type 2 Diabetes Mellitus at Primary Care Level-without 
symptoms 
(Source: Adapted from Appendix 1b, Clinical practice guidelines, Malaysia 2004) 
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1.3.5   Hemoglobin A1c (A1c) 
In the blood stream there are red blood cells, which contain hemoglobin. Glucose sticks to 
the hemoglobin to make a 'glycosylated hemoglobin' molecule, called hemoglobin A1c. 
The more glucose in the blood, the more A1c will be present in the blood. The red blood 
cells that circulate in the body live for about three months before they die off. When sugar 
sticks to these cells, it gives us an idea of how much sugar is around for the preceding 
three months. In most labs, the normal range is 4-5.9 %. In poorly controlled diabetes, its 
8.0% or above, and in well controlled patients it's less than 7.0% (optimal is <6.5%). The 
benefits of measuring A1c is that it gives a more reasonable and stable view of what's 
happening over the course of time (three months), and the value does not bounce as much 
as finger stick blood sugar measurements. There is a direct correlation between A1c levels 
and average blood sugar levels as follows (Engelgau MM, Thompson TJ, Herman WH, et 
al.,1997). 
While there are no guidelines to use A1c as a screening tool, it gives a physician a good 
idea that someone is diabetic if the value is elevated. Right now, it is used as a standard 
tool to determine blood sugar control in patients known to have diabetes.  
The American Diabetes Association currently recommends an A1c goal of less than 7.0%. 
Other Groups such as the American Association of Clinical Endocrinologists feel that an 
A1c of < 6.5% should be the goal (American Diabetes Association, 2007. Diagnosis and 
classification of diabetes mellitus). 
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Table-1.1: Correlation of HbA1c and Blood sugar levels 
Mean blood sugar 
HbA1c (%) 
(mg/dl) (mmol/L) 
7 170 8 
8 205 10 
9 240 12 
10 275 13 
11 310 15 
12 345 17 
 
(Comparison of blood glucose and HbA1c, 
http://medweb.bham.ac.uk/easdec/prevention/what_is_the_hba1c) 
 
Of interest, studies have shown that there is about a 10% decrease in relative risk for 
microvascular disease for every 1 % reduction in HbA1c. So, if a patient starts off with an 
A1c of 10.7% and drops to 8.2%, though there are not yet at goal, they have managed to 
decrease their risk of microvascular complications by about 20%. The closer to normal the 
A1c, the lower the absolute risk for microvascular complications. Data also suggests that 
the risk of macrovascular disease decreases by about 24% for every 1% reduction in 
HbA1c values (American Diabetes Association, 2005). 
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It should be mentioned here that there are a number of conditions in which an A1c value 
may not be accurate. For example, with significant anemia, the red blood cell count is 
low, and thus the HbA1c is falsely low as is similarly in cases of sickle cell disease and 
other hemoglobinopathies (Engelgau MM et al.,1997). 
1.3.6  Chronic Complications of Diabetes 
These diabetes complications are related to blood vessel diseases and are generally 
classified into small vessel disease, such as those involving the eyes, kidneys and nerves 
(Redon J et al, 1994), and large vessel disease involving the heart and blood vessels 
(macrovascular disease,). Diabetes accelerates hardening of the arteries (atherosclerosis) 
of the larger blood vessels, leading to coronary heart disease (angina or heart attack), 
strokes, and pain in the lower extremities because of lack of blood supply (Diabetes 
Control and Complications Trial Research Group, 1993). 
1.3.6(a) Eye Complications 
The major eye complication of diabetes is called diabetic retinopathy. Diabetic 
retinopathy occurs in patients who have had diabetes for at least five years. Diseased 
small blood vessels in the back of the eye cause the leakage of protein and blood in the 
retina. Disease in these blood vessels also causes the formation of small aneurysms 
(microaneurysms), and new but brittle blood vessels (neovascularization). Spontaneous 
bleeding from the new and brittle blood vessels can lead to retinal scarring and retinal 
detachment, thus impairing vision (Diabetic retinopathy study, 1978). 
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To treat diabetic retinopathy a laser is used to destroy and prevent the recurrence of the 
development of these small aneurysms and brittle blood vessels. Approximately 50% of 
patients with diabetes will develop some degree of diabetic retinopathy after 10 years of 
diabetes, and 80% of diabetics have retinopathy after 15 years of the disease. Poor control 
of blood sugar and blood pressure further aggravates eye disease in diabetes (Ciulla TA et 
al., 2003). 
Cataracts and glaucoma are also more common among diabetics. It is also important to 
note that since the lens of the eye lets water through, if blood sugar concentrations vary a 
lot, the lens of the eye will shrink and swell with fluid accordingly. As a result, blurry 
vision is very common in poorly controlled diabetes. Patients are usually discouraged 
from getting a new eyeglass prescription until their blood sugar is controlled. This allows 
for a more accurate assessment of what kind of glasses prescription is required.  
1.3.6(b) Kidney damage 
Kidney damage from diabetes is called diabetic nephropathy. The onset of kidney disease 
and its progression is extremely variable. Initially, diseased small blood vessels in the 
kidneys cause the leakage of protein in the urine. Later on, the kidneys lose their ability to 
cleanse and filter blood. The accumulation of toxic waste products in the blood leads to 
the need for dialysis. Dialysis involves using a machine that serves the function of the 
kidney by filtering and cleaning the blood. In patients who do not want to undergo chronic 
dialysis, kidney transplantation can be considered (The Diabetes Control and 
Complications Trial Research Group, 1995). 
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The progression of nephropathy in patients can be significantly slowed by controlling high 
blood pressure, and by aggressively treating high blood sugar levels. Angiotensin 
converting enzyme inhibitors (ACE inhibitors) or angiotensin receptor blockers (ARBs) 
used in treating high blood pressure may also benefit kidney disease in diabetic patients.  
1.3.6(c) Nerve damage 
Nerve damage in diabetes is called diabetic neuropathy and is also caused by disease of 
small blood vessels. In essence, the blood flow to the nerves is limited, leaving the nerves 
without blood flow, and they get damaged or die as a result (a term known as ischemia). 
Symptoms of diabetic nerve damage include numbness, burning, and aching of the feet 
and lower extremities. When the nerve disease causes a complete loss of sensation in the 
feet, patients may not be aware of injuries to the feet, and fail to properly protect them. 
Shoes or other protection should be worn as much as possible. Seemingly minor skin 
injuries should be attended to promptly to avoid serious infections. Because of poor blood 
circulation, diabetic foot injuries may not heal. Sometimes, minor foot injuries can lead to 
serious infection, ulcers, and even gangrene, necessitating surgical amputation of toes, 
feet, and other infected parts (Obrosova IG, 2003). 
Diabetic nerve damage can affect the nerves that are important for penile erection, causing 
erectile dysfunction (ED, impotence). Erectile dysfunction can also be caused by poor 
blood flow to the penis from diabetic blood vessel disease. Diabetic neuropathy can also 
affect nerves to the stomach and intestines, causing nausea, weight loss, diarrhea, and 
other symptoms of gastroparesis (delayed emptying of food contents from the stomach 
into the intestines, due to ineffective contraction of the stomach muscles).  
